These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33455978)

  • 1. Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
    Wakita M; Asai K; Kubota Y; Koen M; Shimizu W
    J Nippon Med Sch; 2021 Nov; 88(5):423-431. PubMed ID: 33455978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T
    PLoS One; 2022; 17(1):e0261445. PubMed ID: 35077456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
    Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
    Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
    Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
    Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
    Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
    J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF).
    Yokota T; Fukushima A; Kinugawa S; Okumura T; Murohara T; Tsutsui H
    Int Heart J; 2018 Sep; 59(5):976-982. PubMed ID: 30101851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
    Ishikawa T; Maeda T; Hashimoto T; Nakagawa T; Ichikawa K; Sato Y; Kanno Y
    Clin Drug Investig; 2020 Sep; 40(9):847-859. PubMed ID: 32621143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Hosoya T; Sasaki T; Ohashi T
    Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
    J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
    Sezai A; Obata K; Abe K; Kanno S; Sekino H
    Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
    Hosoya T; Ishikawa T; Ogawa Y; Sakamoto R; Ohashi T
    Clin Drug Investig; 2018 Dec; 38(12):1135-1143. PubMed ID: 30219951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
    Hosoya T; Ohno I; Nomura S; Hisatome I; Uchida S; Fujimori S; Yamamoto T; Hara S
    Clin Exp Nephrol; 2014 Dec; 18(6):876-84. PubMed ID: 24448692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
    Bishu K; Deswal A; Chen HH; LeWinter MM; Lewis GD; Semigran MJ; Borlaug BA; McNulty S; Hernandez AF; Braunwald E; Redfield MM
    Am Heart J; 2012 Nov; 164(5):763-770.e3. PubMed ID: 23137508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
    Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
    Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
    Kario K; Nishizawa M; Kiuchi M; Kiyosue A; Tomita F; Ohtani H; Abe Y; Kuga H; Miyazaki S; Kasai T; Hongou M; Yasu T; Kuramochi J; Fukumoto Y; Hoshide S; Hisatome I
    J Clin Hypertens (Greenwich); 2021 Feb; 23(2):334-344. PubMed ID: 33400348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.
    Khalid U; Wruck LM; Quibrera PM; Bozkurt B; Nambi V; Virani SS; Jneid H; Agarwal S; Chang PP; Loehr L; Basra SS; Rosamond W; Ballantyne CM; Deswal A
    Int J Cardiol; 2017 Apr; 233():61-66. PubMed ID: 28185703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Prognostic Significance of Plasma B-Type Natriuretic Peptide Level in Patients With Acute Heart Failure With Reduced, Mid-Range, and Preserved Ejection Fractions.
    Hamatani Y; Nagai T; Shiraishi Y; Kohsaka S; Nakai M; Nishimura K; Kohno T; Nagatomo Y; Asaumi Y; Goda A; Mizuno A; Yasuda S; Ogawa H; Yoshikawa T; Anzai T;
    Am J Cardiol; 2018 Mar; 121(6):731-738. PubMed ID: 29394996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
    Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
    Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.